SCHEMBL5174459

SCHEMBL5174459

Cc1ccccc1Nc1ccc(C(=S)c2ccccc2C)c(Cl)c1

nearest known ligand 0.71

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 13/20 0.71
MAPK13 O15264 12/20 0.71
MAPK12 P53778 12/20 0.71
MAPK11 Q15759 12/20 0.71
MAPT P10636 2/20 0.43
KDM4E B2RXH2 1/20 0.43
HTT P42858 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
DHODH Q02127 1/20 0.42
AVPR2 P30518 1/20 0.41
OXTR P30559 1/20 0.41
AVPR1A P37288 1/20 0.41
GPR27 Q9NS67 1/20 0.40
LMNA P02545 1/20 0.40
POLB P06746 1/20 0.40
TTR P02766 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1908412 0.93 MAPK14 (0.62) MAPK14MAPK13MAPK12MAPK11MAPT
SCHEMBL1897537 0.91 MAPK14 (0.60) MAPK14MAPK13MAPK12MAPK11MAPT
SCHEMBL1899395 0.90 MAPK14 (0.58) MAPK14MAPK13MAPK12MAPK11DHODH
SCHEMBL1907606 0.90 MAPK14 (0.58) MAPK14MAPK13MAPK12MAPK11MAPT
SCHEMBL1907094 0.90 MAPK14 (0.58) MAPK14MAPK13MAPK12MAPK11MAPT
SCHEMBL1906857 0.89 MAPK14 (0.64) MAPK14MAPK13MAPK12MAPK11MAPT
SCHEMBL7075394 0.87 MAPK14 (0.59) MAPK14MAPK13MAPK12MAPK11MAPT
SCHEMBL1897913 0.87 MAPK14 (0.56) MAPK14MAPK13MAPK12MAPK11MAPT
SCHEMBL1898336 0.87 MAPK14 (0.56) MAPK14MAPK13MAPK12MAPK11MAPT
SCHEMBL5173177 0.87 MAPK14 (0.75) MAPK14MAPK13MAPK12MAPK11MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6541670-B2 Antiinflammatory agents LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) 2003-04-01 US claimed
US-20030013770-A1 Aminobenzophenones as inhibitors of il 1b and tnf LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) 2003-01-16 US claimed
EP-1237845-B1 AMINOBENZOPHENONES AS INHIBITORS OF IL-1BETA AND TNF-ALPHA LEO PHARMA AS (DK) 2007-05-23 EP disclosed
US-6541670-B2 Antiinflammatory agents LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) 2003-04-01 US disclosed
US-20030013770-A1 Aminobenzophenones as inhibitors of il 1b and tnf LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) 2003-01-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030013770-A1 Aminobenzophenones as inhibitors of il 1b and tnf IL1B, IL1A, IL6 MAPK14 1553/4885MAPK13 2221/4885MAPK12 1892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.